In a bid to diversify its pipeline, Takeda has signed an exclusive option and license agreement with AC Immune for the latter’s active immunotherapies targeting amyloid beta for Alzheimer’s disease. Through the alliance, which includes a US$100 M upfront payment as well as up to US$2.1 B in milestones, Takeda will receive an exclusive option to license global rights to ACI-24.060, a potential first-in-class vaccine designed to delay or slow Alzheimer’s disease progression. The deal comes shortly after Takeda terminated the development of its only Alzheimer’s drug, TAK-920, following safety concerns in a Phase I trial.